{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:16Z","timestamp":1772119156862,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Contemporary information on epidemiology, healthcare resource utilization (HCRU), costs and clinical outcomes in routine care is essential for value-based decision-making. However, such information remains limited for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in Germany. This study addresses these gaps. This retrospective cross-sectional cost-of-illness study analyzed anonymized statutory health insurance claims data (2015\u20132020). FL Grade I-IIIa (ICD-10: C82.0-C82.3), DLBCL (ICD-10: C83.3) patients were identified via inpatient or outpatient ICD coding. Elixhauser and Charlson Comorbidity Indices were used to describe the general comorbidity burden. FL prevalence increased from 26 to 32 per 100,000 insured persons (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009837 to 1,028), DLBCL prevalence rose from 37 to 45 per 100,000 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091,205 to 1,437). Mean age (FL: 67.0\u2009\u00b1\u200913; DLBCL: 68.6\u2009\u00b1\u200913.6) and sex distribution (FL: 50% female; DLBCL: 44% female) remained stable 2015\u20132020. Mean Charlson Comorbidity Index 4.1\u2009\u00b1\u20092.4 (FL), 4.8\u2009\u00b1\u20092.7 (DLBCL), mean Elixhauser 5.2\u2009\u00b1\u20093.0 (FL), 6.1\u2009\u00b1\u20093.3 (DLBCL). Hospitalization rates: 64% of FL patients (2.0\u2009\u00b1\u20092.3 admissions, 21\u2009\u00b1\u200944.7 days\/year); 78% of DLBCL patients (2.9\u2009\u00b1\u20093.1 admissions, 29\u2009\u00b1\u200947.5 days\/year). Mean annual costs per patient in third-party payers perspective were \u20ac15,258 (FL), \u20ac23,455 (DLBCL). Post-SCT 12-month costs were \u20ac46,270 (FL), \u20ac56,558 (DLBCL) for autologous-SCT, and \u20ac161,662 for allogeneic-SCT (DLBCL only). Rising prevalence calls for ongoing real-world assessment of HCRU and costs. This study supplements limited evidence, highlighting significant economic impact. While health insurance data offer valuable insights, their lack of clinical details necessitates integration with other data sources. Several initiatives are building data spaces to enhance evidence generation; meanwhile, analyses based on single data sources remain valuable to inform practice and policy.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06592-8","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:37:28Z","timestamp":1756805848000},"page":"4625-4635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany"],"prefix":"10.1007","volume":"104","author":[{"given":"Karin","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Moertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Pawlowska-Phelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"20","key":"6592_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"key":"6592_CR2","doi-asserted-by":"crossref","unstructured":"Dreyling, M., et al., Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up <\u2009sup>\u2020\u2009<\u2009sup>\u2606. Annals of Oncology, 2021. 32(3): pp. 298\u2013308","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"6592_CR3","doi-asserted-by":"publisher","first-page":"pv116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H et al (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis,treatment and follow-up <\u2009sup>\u2020. Ann Oncol 26:pv116-v125","journal-title":"Ann Oncol"},{"key":"6592_CR4","unstructured":"Erdmann Fea (2021) Krebs in Deutschland f\u00fcr 2017\/2018. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland, 13.Ausgabe"},{"issue":"1","key":"6592_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM et al (2006) Lymphoma incidence patterns by WHO subtype in the united states, 1992\u20132001. Blood 107(1):265\u2013276","journal-title":"Blood"},{"issue":"5","key":"6592_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol 182(5):633\u2013643","journal-title":"Br J Haematol"},{"issue":"18","key":"6592_CR7","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d\u2019etude des lymphomes de l\u2019adulte. J Clin Oncol 23(18):4117\u20134126","journal-title":"J Clin Oncol"},{"issue":"1","key":"6592_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1182\/asheducation-2016.1.269","volume":"2016","author":"C Casulo","year":"2016","unstructured":"Casulo C (2016) Prognostic factors in follicular lymphoma: new tools to personalize risk. Hematology 2016(1):269\u2013276","journal-title":"Hematology"},{"issue":"27","key":"6592_CR9","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184\u20134190","journal-title":"J Clin Oncol"},{"issue":"16","key":"6592_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808","journal-title":"Blood"},{"issue":"5","key":"6592_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","volume":"94","author":"J Rovira","year":"2015","unstructured":"Rovira J et al (2015) Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol 94(5):803\u2013812","journal-title":"Ann Hematol"},{"issue":"5","key":"6592_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230","volume":"3","author":"G Han","year":"2022","unstructured":"Han G et al (2022) Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428\u2013443. https:\/\/doi.org\/10.1158\/2643-3230","journal-title":"Blood Cancer Discov"},{"issue":"15","key":"6592_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R et al (2018) Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med 378(15):1396\u20131407","journal-title":"N Engl J Med"},{"issue":"3","key":"6592_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","volume":"31","author":"C Sarkozy","year":"2018","unstructured":"Sarkozy C, Sehn LH (2018) Management of relapsed\/refractory DLBCL. Best Pract Res Clin Haematol 31(3):209\u2013216","journal-title":"Best Pract Res Clin Haematol"},{"key":"6592_CR15","unstructured":"Lenz G (2022) e.a., Diffuses gro\u00dfzelliges B-Zell-Lymphom, in Onkopedia Leitlinien"},{"key":"6592_CR16","unstructured":"Buske C (2022) e.a., Follikul\u00e4res Lymphom. Onkopedia Leitlinien"},{"issue":"1","key":"6592_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL et al (2019) Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"1","key":"6592_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"7","key":"6592_CR19","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1097\/HS9.0000000000000736","volume":"6","author":"D Skalt","year":"2022","unstructured":"Skalt D et al (2022) Budget impact analysis of CAR T-cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma in Germany. Hemasphere 6(7):e736","journal-title":"Hemasphere"},{"key":"6592_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M et al (2022) Sampling strategy, characteristics and representativeness of the InGef research database. Public Health 206:57\u201362","journal-title":"Public Health"},{"issue":"5","key":"6592_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"1","key":"6592_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A et al (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8\u201327","journal-title":"Med Care"},{"key":"6592_CR23","unstructured":"Prevalence and incidence of rare diseases: Bibliographic data, in Orphanet Report series. (2022) Orphanet. p. 95"},{"issue":"3","key":"6592_CR24","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1002\/cam4.5160","volume":"12","author":"J D\u00fcrig","year":"2022","unstructured":"D\u00fcrig J et al (2022) Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: final results of the non-interventional study mabscale. Cancer Med 12(3):2739\u20132751. https:\/\/doi.org\/10.1002\/cam4.5160","journal-title":"Cancer Med"},{"key":"6592_CR25","doi-asserted-by":"publisher","unstructured":"Yang X et al (2021) Real-World characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-Cell lymphoma in the US. 26(5):e817\u2013e826. https:\/\/doi.org\/10.1002\/onco.13721","DOI":"10.1002\/onco.13721"},{"issue":"3","key":"6592_CR26","first-page":"2387","volume":"30","author":"MK Tilch","year":"2022","unstructured":"Tilch MK et al (2022) Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany. Support Care Cancer 30(3):2387\u20132395","journal-title":"Support Care Cancer"},{"issue":"5","key":"6592_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1080\/10428194.2016.1228924","volume":"58","author":"MD Danese","year":"2017","unstructured":"Danese MD et al (2017) Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk Lymphoma 58(5):1094\u20131104","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"6592_CR28","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2217\/fon-2022-0112","volume":"18","author":"A Davies","year":"2022","unstructured":"Davies A et al (2022) Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol 18(26):2943\u20132966","journal-title":"Future Oncol"},{"issue":"7","key":"6592_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","volume":"22","author":"B Moertl","year":"2022","unstructured":"Moertl B et al (2022) Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): A health economic perspective. Clin Lymphoma Myeloma Leuk 22(7):474\u2013482","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"6592_CR30","doi-asserted-by":"publisher","first-page":"e0237509","DOI":"10.1371\/journal.pone.0237509","volume":"15","author":"S Tsutsu\u00e9","year":"2020","unstructured":"Tsutsu\u00e9 S et al (2020) Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS ONE 15(8):e0237509","journal-title":"PLoS ONE"},{"issue":"2","key":"6592_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3747\/co.26.4565","volume":"26","author":"S Costa","year":"2019","unstructured":"Costa S et al (2019) Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. Curr Oncol 26(2):108\u2013113","journal-title":"Curr Oncol"},{"issue":"6","key":"6592_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2217\/cer-2018-0094","volume":"8","author":"J Ren","year":"2019","unstructured":"Ren J et al (2019) Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J Comp Eff Res 8(6):393\u2013402","journal-title":"J Comp Eff Res"},{"key":"6592_CR33","doi-asserted-by":"crossref","unstructured":"Borchmann P et al (2022) Healthcare resource utilization and associated costs of German patients with diffuse large B-Cell lymphoma: A retrospective health claims data analysis. Oncol Ther","DOI":"10.1007\/s40487-022-00211-6"},{"issue":"2","key":"6592_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1524-4733.2007.00227.x","volume":"11","author":"RC Lee","year":"2008","unstructured":"Lee RC et al (2008) Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center. Value Health 11(2):221\u2013230","journal-title":"Value Health"},{"key":"6592_CR35","unstructured":"Insitut I (2022) Ausgaben der GKV f\u00fcr Krebsmedikamente. [cited 2023 24.04.2023]; L01 Antineoplastische Mittel]. Available from: https:\/\/www.arzneimittel-atlas.de\/arzneimittel\/l01-antineoplastische-mittel\/ausgaben\/"},{"issue":"2","key":"6592_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjh.18640","volume":"1","author":"R Puckrin","year":"2023","unstructured":"Puckrin R et al (2023) Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma. Br J Haematol 1(2):319\u2013325. https:\/\/doi.org\/10.1111\/bjh.18640","journal-title":"Br J Haematol"},{"issue":"22","key":"6592_CR37","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","volume":"6","author":"G Salles","year":"2022","unstructured":"Salles G et al (2022) Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv 6(22):5835\u20135843","journal-title":"Blood Adv"},{"issue":"2","key":"6592_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/cer-2018-0100","volume":"8","author":"L Mayerhoff","year":"2019","unstructured":"Mayerhoff L et al (2019) Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany. J Comp Eff Res 8(2):121\u2013131","journal-title":"J Comp Eff Res"},{"issue":"2","key":"6592_CR39","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","volume":"5","author":"R Heine","year":"2021","unstructured":"Heine R et al (2021) Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. Hemasphere 5(2):e524","journal-title":"Hemasphere"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06592-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:07Z","timestamp":1761283807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06592-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6592"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06592-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4830530\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karin Berger is employed at the LMU-Clinic, Department Haematology\/Oncology. D. Oberm\u00fcller and D. Pawlowska-Phelan are employed by InGef-Institute for Applied Health Research Berlin GmbH, which received funding from LMU. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by a Scientific Committee, consisting of clinical experts from LMU Klinikum and InGef-Insitute for Applied Health Research Berlin. Due to the non-interventional nature of this research, which used a retrospective anonymized claims dataset, no ethical approval was required for this study. The study followed all the dictates of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}]}}